Prospective study of short and ultrashort regimens of gonadotropinreleasing hormone agonist in an in vitro fertilization program
|
|
- Stephen Richard
- 5 years ago
- Views:
Transcription
1 FERTILITY AND STERILITY Copyright 1992 The American Fertility Society Printed on acid-free paper in U.S.A. Prospective study of short and ultrashort regimens of gonadotropinreleasing hormone agonist in an in vitro fertilization program Umesh Acharya, M.R.C.O.G.* Stewart Irvine, M.D. Mark Hamilton, M.D. Allan Templeton, M.D. Assisted Reproduction Unit, Department of Obstetrics and Gynaecology, University of Aberdeen, Aberdeen Maternity Hospital, Aberdeen, Scotland. Objective: To assess the usefulness of the ultrashort regimen of gonadotropin-releasing hormone agonist (GnRH-a) in ovulation induction in an in vitro fertilization (IVF) program. Design: A prospective randomized trial comparing short and ultrashort regimens of GnRH-a. Setting: Aberdeen Assisted Reproduction Unit. Patients: Forty-eight patients having IVF for the first time were randomized between the two protocols. Main Outcome Measures: Response to ovarian stimulation and occurrence of spontaneous luteinizing hormone (LH) surges. Results: In ovulation induction, fertilization, and pregnancy rates the ultrashort regimen produces results that were no different to the short regimen but it did not always prevent an LH surge. Conclusion: The ultrashort regimen can be a useful alternative for ovarian stimulation of patients undergoing IVF. Fertil Steril1992;58: Key Words: In vitro fertilization, gonadotropin-releasing hormone agonist, ovarian stimulation, short and ultrashort regimen Induction of multiple ovulation followed by in vitro fertilization (IVF) and embryo transfer has become a widely accepted treatment of infertility. Initially' the anti-estrogen clomiphene citrate (CC) was used, followed by the combination of CC and human menopausal gonadotropin (hmg) for ovulation induction. Early attempts at stimulated IVF cycles were hampered by the occurrence of a premature luteinizing hormone (LH) surge and the inability to undertake oocyte recovery at convenient times. This problem has been partially overcome with the introduction of gonadotropin-releasing hormone agonists (GnRH-a). Initially GnRH-a was com- Received March 12, 1992; revised and accepted August 18, * Reprint requests: Umesh Acharya, M.R.C.O.G., Assisted Reproduction Unit, Department of Obstetrics and Gynaecology, University of Aberdeen, Aberdeen Maternity Hospital, Cornhill Road, Aberdeen AB9 2ZD, Scotland. menced in the luteal phase of the pretreatment cycle (1, 2) or during menstruation (3-5) and was continued until complete suppression of pituitary gonadotropin was achieved. This method results in down regulation in the space of 2 weeks and has been referred to as long course treatment. This was followed by the so-called short course treatment of GnRH -a whereby GnRH -a was given in the early follicular phase together with ovarian stimulation. The latter form of treatment achieves comparable results to the long course and is better tolerated by patients (2, 6, 7). More recently there have been reports of the ultrashort protocol in which the GnRH -a therapy is administered for 3 to 4 days only (8-10). The present study is the first prospective randomized study to compare the use of short and ultrashort protocols of GnRH -a therapy in achieving superovulation for purposes of IVF. This study Acharya et al. Short and ultrashort regimens in IVF 1169
2 aimed to examine whether the results obtained using the ultrashort protocol were similar to those obtained using the short protocol and to review any deleterious effects that the ultrashort protocol may have had, particularly the occurrence of a premature LH surge was monitored. Patients MATERIALS AND METHODS Patients having their first IVF treatment were recruited from the Aberdeen IVF program. Table 1 shows the characteristics of patients undergoing treatment. Forty-eight patients were recruited for the study and randomly allocated to one or other of the following protocols. Randomization was undertaken using sealed envelopes. There were 24 patients in each group. In group 1, (short protocol) norethisterone (Primolut N; Schering Pharmaceuticals, Burgess Hill, United Kingdom) 5 mg two times per day was commenced on day 21 of the cycle for 7 to 14 days. The use of norethisterone in the preceding cycle to delay menstruation has been previously described (11, 12). The use of norethisterone has been shown not to affect the outcome of IVF treatment (13). After the completion of norethisterone, a basal scan was performed and if the serum estradiol (E2) level was <70 pmoljl «19 pgjml), buserelin acetate (Suprefact; Hoechst UK Ltd., Middlesex, United Kingdom) 500 J.lgjSC was commenced the following day (day 1). This was continued until the day of human chorionic gonadotropin (hcg) administration. Superovulation was commenced initially at 300 IU of hmg (Pergonal; Serono Laboratories UK Ltd., Welwyn Garden City, United Kingdom) on day 2 for 3 days, followed by 225 IU on the fourth day and 150 IUjd for the rest of the cycle (till the day of hcg administration), the dose being adjusted according to ovarian response. Serial scans were performed using a Diasonics 250 ultrasound (US) machine (Diasonics Sonotron, Bedford, United Kingdom) equipped with a 7.5-MHz vaginal probe. Ten thousand international units of hcg was administered when three follicles were> 16 mm diameter and E2 > 2,000 pmoljl (545 pgjml). Vaginal oocyte recovery was carried out 34 hours later under US guidance. Embryo replacement was undertaken 48 hours after the oocyte recovery. Sperm were prepared by the swim-up technique and the motile sperm were used for insemination. In group 2 (ultrashort protocol) the procedure was similar except that buserelin acetate was adminis- Table 1 Patient Characteristics in Two Treatment Groups Ultrashort Short protocol protocol (n = 24) (n = 24) Female age (y) 34 (26 to 43)* 32 (26 to 43)* Duration of infertility (y) 5.0 (2-11)* 4.8 (1-20)' Etiology of infertility Tubal 10 (41. 7)t 13 (54.2) Unexplained 8 (33.3) 4 (16.7) Male 3 (12.5) 5 (20.8) Endometriosis 3 (12.5) 2 (8.3) Outcome Menstruation 17 (70.8)t 13 (54.2) Pregnancies 2 (8.3) 5 (20.8) Failed fertilization 3 (12.5) 1 (4.2) Poor stimulation 1 (4.2) 1 (4.2) Overstimulated 1 (4.2) 3 (12.5) Other 0 1 (4.2), Values are medians with ranges in parentheses. t Values in parentheses are percents. tered for only 3 days (days 1 to 3). In both groups blood was taken on the 5th, 10th, and 15th day after hcg administration (hcg +5, hcg + 10, and hcg + 15) for progesterone (P) and E2 levels to monitor the luteal phase. Luteal support was given by administering 2,500 IU of hcg on the day of embryo replacement. Assays Serum E2 and P levels were measured by radioimmunoassay (RIA, Estradiol Coat-A-Count; Diagnostic Products Corporation Ltd., Oxon, United Kingdom and P using Amerlex-M Kit; Amerlite Diagnostics Ltd., Amersham, United Kingdom), the details of which have been previously reported (14). Serum LH was also measured by an RIA (LH MAlA clone; Serono Diagnostics, Fleet, Hampshire, United Kingdom). The LH intra-assay coefficient of variation (CV) was 4.4% and the interassay CV was 6.3%. Statistics No assumptions were made regarding the distribution of the data and consequently a nonparametric method (Mann-Whitmey U-test) was used for comparison between groups. Analysis of variance was used to compare outcome measures between the two groups. RESULTS Both groups were similar with respect to age, duration of infertility, and indication for IVF as can 1170 Acharya et al. Short and ultrashort regimens in IVF Fertility and Sterility
3 be seen from Table 1. Analysis of variance showed that the distribution of etiology of infertility in these two groups was not significantly different and the percentage of patients with primary infertility (83.3%, short; 75%, ultrashort) and secondary infertility (16.7%, short; 25%, ultrashort) was similar in both groups. No difference was found in the stimulation requirements (Table 2) or in the response to stimulation as measured by E2 values (Fig. 1) in the two groups. There was no difference in the number of follicles aspirated or number of oocytes obtained per patient; however, a higher number of oocytes cleaved per patient in the ultrashort group but this did not reach significance. This did not appear to be related to the semen quality as there was no difference in the sperm concentration or grade III and grade IV motility of sperm used for insemination. The median sperm concentrations were 9 X 10 6 /ml and 5 X ml in the first and second groups respectively, the median grade III motilities were 77.5% and 76.5%, respectively, and grade IV motilities were 10% and 8.5%, respectively. However, when the embryos did cleave, the grading distribution was the same in both groups, as was the number of patients having three embryos transferred (we follow the Human Fertilization and Embryology Authority's guidelines in the "Code of Practice" of transferring no more than three embryos in each cycle). The embryos were graded on a scale of 0 to 10 according to recommended embryological criteria (15, 16). Table 2 Stimulation, Ovarian, and Embryologic Details in Two Groups Duration of hmg administration (d) Amount of hmg (ampules 75 IU FSH; 75 IV LH) No. of days from basal scan to oocyte recovery No. of follicles aspirated per patient No. of oocytes obtained per patient No. of oocytes cleaved per patient Grade of embryo transferred No. of patients having three embryos transferred Short protocol 11 (9-16)" 28 (17-72) 14 (12-18) 9 (1-26) 7 (1-17) 3.5 (0-13) 1 (2.2)t 6 (13.0) 22 (47.8) 17 (37.0) 13 (54.2) * Values are medians with ranges in parentheses. t Values in parentheses are percents. Ultrashort protocol 11 (7-18) 28 (14-80) 15 (12-18) 12 (1-24) 8 (1-20) 6 (0-15) 1 (2.0) 5 (9.8) 21 (41.2) 24 (47.1) 15 (62.5) S E Q. N W a Days from oocyte recovery Figure 1 Graph of E2 values with days from oocyte recovery in ultrashort (- 0 - median and 95% confidence intervals; CI) and short regimens (-+- median and 95% Cn. There were five pregnancies in the ultrashort group and two in the short group. Clearly this result did not reach statistical significance and could not be expected to do so in a study of this size. A much larger study would be required to achieve this. The pregnancy rate per embryo transfer was 27.8% (51 18) in the ultrashort group and 10.5% (2/19) in the short group. With regard to the pregnancy outcomes, of the 5 in the ultrashort group, 4 resulted in live births (2 singletons and 2 sets of twins) and 1 resulted in a missed abortion. In the short group both pregnancies resulted in live singleton births. A premature LH surge, resulting in cancellation of the cycle, occurred once in the ultrashort group but did not occur in the short group. The LH values on the day of hcg administration ranged from 0.5 to 1.6 lull. In the patient with the LH surge, the surge occurred on day 15. The LH values before this day did not exceed 3.0 lull. The LH values on day 14, 15, and 16 were 6.3, 21.2, and 8.9 lull, respectively. The corresponding P values were 1.3, 2.2, and 5.5 nmol/l (0.41, 0.69, and 1.73 ng/ml), and the E2 values were 2,970, 4,790, and 2,750 pmoljl (809.0, 1,304.8, and pg/ml), respectively, demonstrating that this was a true LH surge. This patient had 10 days of pretreatment with norethisterone. This cycle was cancelled because at the onset of the LH surge the three largest follicles had a mean diameter of 15.3 mm (16.3, 14.7, and 14.5 mm) only. It can be seen that although this patient's response was slower than the median response, it would be within the range for that particular group of patients. There were no biochemical or US evidence of pre- Acharya et al. Short and ultrashort regimens in IVF 1171
4 mature luteinization in any of the other patients in the study. The number of patients with overstimulation was the same in both groups. There was no difference in the luteal phase E2 levels. On hcg +5, E2 was 2,300 pmol/l (626.5 pg/ml) in the short group and 1,350 pmol/l (367.8 pg/ml) in the ultrashort group. Similarly on hcg +10, E2 values were 4,500 pmol/l (1,225.8 pg/ml) and 4,200 pmol/l (1,144.1 pg/ml), and on hcg + 15, E2 values were 160 pmol/l (43.6 pg/ml) and 350 pmol/l (95.4 pg/ml). Progesterone values 5 and 15 days after hcg administration were not significantly different, i.e., 127 nmol/l (39.9 ng/ml) and nmol/l (37.0 ng/ml) on hcg +5, in the ultrashort and short protocols, respectively, and 6.5 nmol/l (2.0 ng/ml) and 5.5 nmol/l (1.7 ng/ml), respectively, on hcg In the midluteal phase (hcg + 10) the P value was significantly raised (P < 0.05) in the ultrashort group, nmol/l (86.2 ng/ml), compared with the short group, nmol/l (39.9 ng/ml). DISCUSSION This study compares the use of the short and ultrashort protocols of GnRH -a administration in the context of IVF ovulation induction regimens. Although the long and short protocols have been shown to be useful (2,4,6,7,17), this study confirms that treatment using the ultrashort protocol is a satisfactory alternative. The follicular response and the number of oocytes obtained were very similar for both regimens. The cleavage and the pregnancy rate were slightly higher in the ultrashort group, but this did not reach statistical significance (a much larger study would be required to address this question). Similarly, there was no difference in the incidence of ovarian overstimulation or the number of patients reaching embryo replacement. It would appear that the ultrashort regimen is more convenient for the patient, GnRH-a being injected for only 3 days compared with a median of 12 days for the short protocol. This shorter duration of agonist administration would also have implications for the cost of and compliance with treatment. There was also a higher pregnancy rate with the ultrashort protocol but this did not reach significance in this small study. However the ultrashort regimen did not totally prevent the occurrence of a spontaneous LH surge. Smitz et al. (10) using the agonist (500 Ilg/d SC, day 3 to 5) in 10 endocrino Acharya et al. Short and ultrashort regimens in IVF logically normal patients also found that it did not always prevent an LH surge. Howles et al. (8) studied seven patients who had responded poorly to CC and hmg previously and had high tonic LH levels. In their small study they found that administering GnRH-a (500 Ilg/d SC) on days 1 to 3 of menstrual cycle significantly reduced the urinary LH output in the latter stages of follicular development. Martikainen et al. (9) administered GnRH-a (200 Ilg IN three times per day) and found that it prevented the LH surge although in their study it was administered for 4 days (days 1 to 4). In our study, we observed that the midluteal P was significantly raised in the ultrashort group, possibly because of the fact that more follicles were aspirated in this group (12 versus 9). This study is the first prospective randomized controlled trial of short versus ultrashort GnRH-a regimens. The efficacy of the ultrashort regimen is confirmed. It is simpler to use and is more convenient for the patient, requiring fewer subcutaneous injections. The shorter duration of GnRH-a administration makes it more cost effective and no significant compromise is apparent in terms of IVF, outcome, embryo quality, and pregnancy rates although premature luteinization is not always prevented by this regimen. We have established that the ultrashort regimen is a useful alternative to the long and short regimens in ovarian stimulation of patients undergoing IVF. REFERENCES 1. de Ziegler D, Cedars MI, Randle D, Lu JKH, Judd HL, Meldrum DR. Suppression of the ovary using a gonadotropin releasing-hormone agonist prior to stimulation for oocyte retrieval. Fertil SterilI987;48: Zorn JR, Barata M, Brami C, Epelboin S, Nathan C, Papageorgiou G, et al. Ovarian stimulation for in vitro fertilization combining administration of gonadotropins and blockade of the pituitary with D-Trp6 -LHRH microcapsules: pilot studies with two protocols. Hum Reprod 1988;3: Porter RN, Smith W, Craft IL, Abdulwahid NA, Jacobs HS. Induction of ovulation for in-vitro fertilization using buserelin and gonadotropins. Lancet 1984;2: Wildt L, Diedrich K, van der Ven H, Al Hasani S, Hubner H, Klasen R. Ovarian hyperstimulation for in-vitro fertilization controlled by GnRH agonist administered in combination with human menopausal gonadotropins. Hum Reprod 1986;1: Smitz J, Devroey P, Braeckmans P, Camus M, Khan I, Staessen C, et al. Management of failed cycles in an IVF / GIFT programme with the combination of a GnRH analogue and hmg. Hum Reprod 1987;2: Frydman R, Belaisch-Allart J, Parneix I, Forman R, Hazout A, Testart J. Comparison between flareup and down regulation effects of luteinizing hormone releasing hormone ag- Fertility and Sterility
5 onists in an in vitro fertilization program. Fertil Steril1988;50: Acharya U, Small J, Randall J, Hamilton M, Templeton A. Prospective study of short and long regimens of gonadotropinreleasing hormone agonist in in vitro fertilization program. Fertil Steril 1992;57: Howles CM, Macnamee MC, Edwards RG. Short term use of an LHRH agonist to treat poor responders entering an in vitro fertilization programme. Hum Reprod 1987;2: Martikainen H, Ronnberg L, Tapanainen J, Puistola U, Orava M, Kauppila A. Endocrine responses to gonadotropins after LHRH agonist administration on cycle days 1-4: prevention of premature luteinization. Hum Reprod 1990;5: Smitz J, Bollen N, Camus M, Devroey P, Wisanto A, Van Steirteghem AC. Short term use of bus ere lin in combination with human menopausal gonadotropins for ovarian stimulation for in vitro fertilization in endocrinologically normal women. Hum Reprod 1990;5: Templeton A, Van Look P, Lumsden MA, Angell R, Aitken J, Duncan A W, et al. The recovery of pre-ovulatory oocytes using a fixed schedule of ovulation induction and follicle aspiration. Br J Obstet Gynaecol 1984;91: Messinis IE, Templeton A, Angell R, Aitken J. A comparison of fixed regimens for obtaining human cleaving oocytes for research purposes. Br J Obstet Gynaecol 1986;93: Wardle PG, Foster PA, Mitchell JD, McLaughlin EA, Williams JAC, Corrigan E, et al. Norethisterone treatment to control timing of the IVF cycle. Hum Reprod 1986;1: Mahmood TA, Templeton A. Peritoneal fluid volume and sex steroids in the pre-ovulatory period in mild endometriosis. Br J Obstet Gynaecol 1991;98: Mohr K, Trounson A. In vitro fertilization and embryo growth. In: Wood C, Thomson A, editors. Clinical in vitro fertilization. Heidelberg: Springer-Verlag, 1984: Watt JL, Templeton AA, Messinis I, Bell L, Cunningham P, Duncan RO. Trisomy 1 in an eight cell human pre-embryo. J Med Genet 1987;24: Antoine JM, Salat-Baroux J, Alvarez S, Cornet D, Tibi C, Mandelbaum J, et al. Ovarian stimulation using human menopausal gonadotropins with or without LHRH analogues in a long protocol for in vitro fertilization: a prospective randomized comparison. Hum Reprod 1990;5: Acharya et al. Short and ultrashort regimens in IVF 1173
Programming in vitro fertilization for a 5- or 3-day week
Ass~st.d.reproductive tec"no'ogy FERTILITY AND STERILITY Copyright I[J 1991 The American Fertility Society Printed on acid-free paper in U.S.A. Programming in vitro fertilization for a 5- or 3-day week
More informationFixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol
Yamanashi Med. J. 14(3), 77 ~ 82, 1999 Original Article Fixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol Tsuyoshi KASAI and Kazuhiko
More informationBulent Urman, M.D.* Margo R. Fluker, M.D. Basil Ho Yuen, M.B., Ch.B.t
FERTILITY AND STERILITY Copyright c 1992 The American Fertility Society Vol. 57, No.6, June 1992 Printed on acid-free paper in U.S.A. The outcome of in vitro fertilization and embryo transfer in women
More informationTimur Giirgan, M.D.* Bulent Urman, M.D. Hakan Yarali, M.D. Hakan E. Duran, M.D.
FERTILITY AND STEFULI~ Vol. 68, No. 3, September 1997 Copyright 1997 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Published by Elsevier Science Inc. Follicle-stimulating
More informationA controlled study of gonadotropin-releasing hormone agonist (buserelin acetate*) for folliculogenesis in routine in vitro fertilization patients
FERTILITY AND STERILITY Copyright" 1991 The American Fertility Society Vol. 56, No. 3, September 1991 Printed on acid-free paper in U.S.A. A controlled study of gonadotropin-releasing hormone agonist (buserelin
More informationOvarian response in three consecutive in vitro fertilization cycles
FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Ovarian response in
More informationGonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome
FERTILITY AND STERILITY Copyright e 1993 The American Fertility Society Vol. 59, No.3, March 1993 Printed on acid-free paper in U.S.A. Gonadotropin-releasing hormone agonist reduces the miscarriage rate
More informationIn vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome
Assisted reproductive techno.logy FERTILITY AND STERILITY Vol. 60, No.5, November 1993 Copyright 199a The American Fertility Society Printed on acid-free paper in U. S. A. In vitro fertilization and embryo
More informationAssisted reproductive technology
Assisted reproductive technology FERTILITY AND STERILITY Vol. 60, No.2, August 1993 Copyright 'c; 199:~ The American Fertility Society Printed on acid-free paper in U. S. A. Natural cycle in vitro fertilization-embryo
More informationIn Vitro Fertilization and Embryo Transfer
Acta Medica et Biologica Vol. 41, No.4, 171-176, 1993 The Influence of Low Ovarian Response on the Results of In Vitro Fertilization and Embryo Transfer Hirofumi HIRASAWA Department of Obstetrics and Gynecology,
More informationDoes previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?
J Assist Reprod Genet (26) 23:427 431 DOI 1.17/s1815-6-965-x ASSISTED REPRODUCTION Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation
More informationDoes triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *
Middle East Fertility Society Journal Vol. 11, No. 2, 2006 Copyright Middle East Fertility Society Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Amany A.M. Shaltout, M.D. Mohamed
More informationA Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist
1 *, ** * * * ** A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist Yoon Sung Nam, Nam Keun Kim*, Eun Kyung Kim**, Hyung Min Chung** and Kwang
More informationA prospective randomized study comparing aspiration only with aspiration and flushing for transvaginal ultrasound-directed oocyte recovery
FERTILITY AND STERILITY Vol. 58, No.2, August 1992 Copyright e 1992 The American Fertility Society Printed on acid-free paper in U.S.A. A prospective randomized study comparing aspiration only with aspiration
More informationin vitro fertilization
FERTILITY AND STERILITY VOL 69, NO. 6, JUNE 1998 Copyright (#1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Elevated levels of basal
More informationAgonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic
More informationArticle Effect of cetrorelix dose on premature LH surge during ovarian stimulation
RBMOnline - Vol 16. No 6. 2008 772-777 Reproductive BioMedicine Online; www.rbmonline.com/article/3181 on web 18 April 2008 Article Effect of cetrorelix dose on premature LH surge during ovarian stimulation
More informationProspective study of a modified gonadotropin-releasing hormone agonist long protocol in an in vitro fertilization program
FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Printed on acid-free paper in U. s. A. Prospective study of a modified gonadotropin-releasing hormone agonist long protocol in an in
More informationPituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H.
UvA-DARE (Digital Academic Repository) Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H. Link to publication Citation for published version (APA): Mochtar, M. H.
More informationHerjan Coelingh Bennink, M.D.:j: Andre Van Steirteghem, M.D., Ph.D.* Paul Devroey, M.D., Ph.D.*
J FERTILITY AND STERILITY@ Copyright 't; 1996 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing
More informationMenstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
Human Reproduction Vol.21, No.4 pp. 1012 1017, 2006 Advance Access publication December 8, 2005. doi:10.1093/humrep/dei415 Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
More informationGraham Burford, Ph.D. Albert Bernard, B.Sc. Bernard Bentick, M.R.C.O.G. Robert W. Shaw, M.D.t Claire A. Iflland, M.B.
FERTILITY AND STERILITY Copyright 1988 The American Fertility Society Printed in U.S.A. A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after
More informationDepartment of Gynaecology and Reproductive Medicine, University Hospital, University of Western Ontario, London, Ontario, Canada
FERTILITY AND STERILITY Copyright 1992 The American Fertility Society Printed on acid-free paper in U.S.A. Randomized, prospective comparison of luteal leuprolide acetate and gonadotropins versus clomiphene
More informationUse of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to friendly IVF?
Human Reproduction Vol.17, No.8 pp. 2022 2026, 2002 Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to friendly IVF? J.B.Engel, M.Ludwig 1, R.Felberbaum,
More informationComparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization
Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization Peter Kovacs, M.D., a Timea Kovats, M.D., a Artur Bernard,
More informationAlternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment
Human Reproduction Vol., No.11 pp. 319 3197, 5 Advance Access publication July 1, 5. doi:.93/humrep/dei Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to
More informationClinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.
UvA-DARE (Digital Academic Repository) Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. Link to publication Citation for published version (APA): Al-Inany,
More informationUse of buserelin acetate in an in vitro fertilization program: a comparison with classical clomiphene citrate-human menopausal gonadotropin treatment
FERTILITY AND STERILITY Copyright'" 1990 The American Fertility Society Printed on acid-free paper in U.S.A. Use of buserelin acetate in an in vitro fertilization program: a comparison with classical clomiphene
More informationArticle Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles
RBMOnline - Vol 13. No 3. 2006 326 330 Reproductive BioMedicine Online; www.rbmonline.com/article/1911 on web 13 June 2006 Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist
More informationInfertility treatment
In the name of God Infertility treatment Treatment options The optimal treatment is one that provide an acceptable success rate, has minimal risk and is costeffective. The treatment options are: 1- Ovulation
More informationArticle Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment
RBMOnline - Vol 7. No 2. 185 189 Reproductive BioMedicine Online; www.rbmonline.com/article/900 on web 18 June 2003 Article Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix,
More informationPremature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles
Arch Gynecol Obstet (2010) 281:747 752 DOI 10.1007/s00404-009-1248-0 REPRODUCTIVE MEDICINE Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles Esra
More informationPatterns of serum-luteinizing hormone surges in stimulated cycles in relation to injections of human chorionic gonadotropin*
FERTILITY AND STERILITY Copyright ov 1990 The American Fertility Society Printed on acid-free paper in U.S.A. Patterns of serum-luteinizing hormone surges in stimulated cycles in relation to injections
More informationLOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
More informationJinan Bekir, M.D. Amma Kyei-Mensah, M.D. Seang-Lin Tan, M.D.
FERTILITY AND STERILITY Copyright ~ 1995 American Society for Reproductive Mediciue Vol. 64, No.4, October 1995 Printed on acid-free paper in U. S. A. Administration of progestogens to hasten pituitary
More informationJoelle Taieb, M.D.t Irving M. Spitz, M.D. Philippe Bouchard, M.D. II
FERTILITY AND STERILITY Copyright 1991 The American Fertility Society Printed on acid-free paper in U.S.A. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing
More informationIs it the seed or the soil? Arthur Leader, MD, FRCSC
The Physiological Limits of Ovarian Stimulation Is it the seed or the soil? Arthur Leader, MD, FRCSC Objectives 1. To consider how ovarian stimulation protocols work in IVF 2. To review the key events
More informationEffect of baseline ovarian cysts on in vitro fertilization and gamete intrafallopian transfer cycles*
FERTILITY AND STERILITY Copyright 1991 The American Fertility Society Printed on acid-free paper in U.S.A. Effect of baseline ovarian cysts on in vitro fertilization and gamete intrafallopian transfer
More informationPituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H.
UvA-DARE (Digital Academic Repository) Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H. Link to publication Citation for published version (APA): Mochtar, M. H.
More information' ' ' ' ' ' ' ' COMPARISON BETWEEN HIGHLY PURIFIED--FSH AND HMG FOR SUPEROVULATION IN WOMEN UNDERGOING IN VITRO FERTILIZATION ORIGINAL RESEARCH
' ' ' ' ORIGINAL RESEARCH ' ' ' ' COMPARISON BETWEEN HIGHLY PURIFIED--FSH AND HMG FOR SUPEROVULATION IN WOMEN UNDERGOING IN VITRO FERTILIZATION Pierre Miron, MD, FRCSC, 1 Robert Casper, MD, FRCSC,2 Louise
More informationIranian Journal of Reproductive Medicine Vol. 2. No.1 pp 29-33, 2004
Efficacy of Low Dose, Long-acting Gonadotropin Releasing Hormone Analogues (GnRH-a) Compared with Daily Injections of Short-acting GnRH-a in ART Cycles Robabeh Taheripanah M.D. 1, Mohammad A. Karimzadeh
More informationSTIMULATION AND OVULATION TRIGGERING
STIMULATION AND OVULATION TRIGGERING Professor IOANNIS E. MESSINIS MD, PhD (Aberdeen, UK), FRCOG (UK) Department of Obs/Gynae University of Thessaly Larissa, GREECE DISCLOSURE Nothing to disclose Learning
More informationPrognostic value of day 3 estradiol on in vitro fertilization outcome*
FERTILITY AND STERILITY Vol. 64, No.6, December 1995 Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Prognostic value of day 3 estradiol on in vitro fertilization
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More informationUtility of in vitro fertilization at diagnostic laparoscopy*
FERTILITY AND STERILITY Copyright" 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Utility of in vitro fertilization at diagnostic laparoscopy* Paul R. Gindoff, M.D.t Jerry L.
More informationLuteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
More informationPrinciples of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
More informationAssisted Reproduction. Rajeevi Madankumar, 1,2 James Tsang, 1 Martin L. Lesser, 1 Daniel Kenigsberg, 1 and Steven Brenner 1 INTRODUCTION
( C 2005) DOI: 10.1007/s10815-005-4912-8 Assisted Reproduction Clomiphene citrate induced ovulation and intrauterine insemination: effect of timing of human chorionic gonadotropin injection in relation
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Recombinant versus urinary follicle-stimulating hormone in intrauterine insemination cycles: a prospective, randomized analysis of cost effectiveness Gerli S, Casini M L, Unfer V, Costabile L, Bini V,
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,
More informationDifferent implantation rates after transfers of cryopreserved embryos originating from donated oocytes or from regular in vitro fertilization*
FERTILITY AND STERILITY Vol. 54, No. 4, October 1990 Copyright co 1990 The American Fertility Society Printed on acid-free paper in U.S.A. Different implantation rates after transfers of cryopreserved
More informationAssisted Reproduction. By Dr. Afraa Mahjoob Al-Naddawi
Assisted Reproduction By Dr. Afraa Mahjoob Al-Naddawi Learning Objectives: By the end of this lecture, you will be able to: 1) Define assisted reproductive techniques (ART). 2) List indications for various
More informationIvf day 6 estradiol level
Ivf day 6 estradiol level Search It is also important to measure the estradiol on day 3. Day 2 is fine. The reason its day 3 is 15-20 years ago, the IVF medications were always started on day 3. Day 3
More informationStimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in vitro fertilization
FERTILITY AND STERILITY Copyright" 1991 The American Fertility Society Vol. 55, No.2, February 1991 Printed on acid-free paper in U.S.A. Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing
More informationI. ART PROCEDURES. A. In Vitro Fertilization (IVF)
DFW Fertility Associates ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Welcome to DFW Fertility Associates/ Presbyterian-Harris Methodist Hospital ARTS program. This document provides an overview of treatment
More informationGonadotrophin treatment in patients with Polycystic Ovary Syndrome
Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218
More informationUnderstanding Infertility, Evaluations, and Treatment Options
Understanding Infertility, Evaluations, and Treatment Options Arlene J. Morales, M.D., F.A.C.O.G. Fertility Specialists Medical Group, Inc. What We Will Cover Introduction What is infertility? Briefly
More informationINTRODUCTION. Kang Woo Cheon, Sang Jin Song, Bum Chae Choi, Seung Chul Lee*, Hong Bok Lee*, Seung Youn Yu*, and Keun Jai Yoo
J Korean Med Sci 2008; 23: 662-6 ISSN 1011-8934 DOI: 10.3346/jkms.2008.23.4.662 Copyright The Korean Academy of Medical Sciences Comparison of Clinical Efficacy between a Single Administration of Long-Acting
More informationInterpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used
Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara
More informationVanessa N. Weitzman, M.D., Lawrence Engmann, M.D., Andrea DiLuigi, M.D., Donald Maier, M.D., John Nulsen, M.D., and Claudio Benadiva, M.D.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol
More information(BMI)=18.0~24.9 kg/m 2 ;
33 10 Vol.33 No.10 2013 10 Oct. 2013 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2013.10.0672 E-mail: randc_journal@163.com - ( 400013) : () GnRH-a - () : IVF- ET 233 A (I~II 102 ) B (III~IV
More informationDepartment of Obstetrics and Gynecology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas
FERTILITY AND STERILITY Copyright 1991 The American Fertility Society Vol. 56, No. 2, August 1991 Printed on ocid-free paper in U.S.A. Follicular size at the time of human chorionic gonadotropin administration
More informationOriginal Article. Fauzia HaqNawaz 1*, Saadia Virk 2, Tasleem Qadir 3, Saadia Imam 3, Javed Rizvi 2
Original Article Comparison of Letrozole and Clomiphene Citrate Efficacy along with Gonadotrophins in Controlled Ovarian Hyperstimulation for Intrauterine Insemination Cycles Fauzia HaqNawaz 1*, Saadia
More informationEndocrinology of the Female Reproductive Axis
Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN
More informationMilder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization
Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization Revelli et al. Reproductive Biology and Endocrinology 2011, 9:25 Presenter: R2 孫怡虹 Background
More informationOriginal Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and embryo transfer
Int J Clin Exp Med 2015;8(7):11327-11331 www.ijcem.com /ISSN:1940-5901/IJCEM0008838 Original Article Impact of estrogen-to-oocyte ratio on live birth rate in women undergoing in vitro fertilization and
More informationEffect of Body Mass Index on IVF Procedure and Outcome
ORIGINAL STUDY Effect of Body Mass Index on IVF Procedure and Outcome Al Marzooqi T. Obstetrics and Gynecology Department, Women's Hospital, Hamad Medical Corporation, Doha, Qatar Declaration of interests:
More informationFactors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2015;42(2):67-71 Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles Ju Hee Park
More informationThe effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study
Clinical research The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Ashraf Moini 1,2, Shahrzad Zadeh Modarress 3, Elham Amirchaghmaghi
More informationRelevance of LH activity supplementation
Relevance of LH activity supplementation in ovulation induction Franco Lisi Servizio di Fisiopatologia della Riproduzione Clinica Villa Europa Roma, Italia Comprehension of the role of LH in follicular
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 September 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 September 2010 100 µg/0.5 ml, solution for injection B/1 prefilled syringe + 1 needle (CIP code: 374 590-1) 150
More informationDifferent follicle stimulating hormone/luteinizing hormone ratios for ovarian stimulation
Human Reproduction vol.8 no.9 pp. 1387-1391, 1993 Different follicle stimulating hormone/luteinizing hormone ratios for ovarian stimulation LJ.M.Duijkers 1 ' 4, H.M.Vemer 1, J.M.G.HoUanders 1, W.N.P.Willemsen
More informationthat induce morphologic (4, 5) and biochemical (6) endometrial alterations relevant to uterine receptivity.
FERTILITY AND STERILITY VOL. 70, NO. 2, AUGUST 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. 12 Increasing uterine
More informationK.W.Fuh, X.Wang, A.Tai, I.Wong and R.J.Norman 1
Human Reproduction vol.12 no.10 pp.2162 2166, 1997 Intrauterine insemination: effect of the temporal relationship between the luteinizing hormone surge, human chorionic gonadotrophin administration and
More informationFemale Reproductive System. Lesson 10
Female Reproductive System Lesson 10 Learning Goals 1. What are the five hormones involved in the female reproductive system? 2. Understand the four phases of the menstrual cycle. Human Reproductive System
More informationLUTEAL PHASE SUPPORT. Doç. Dr. Nafiye Yılmaz. Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi
LUTEAL PHASE SUPPORT Doç. Dr. Nafiye Yılmaz Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi TAJEV, 2014 1 ART & success *Live birth rate 2 Optimal luteal phase Etiology of luteal phase deficiency
More informationThe predictive value of idiopathic failure to fertilize on the first in vitro fertilization attempt*
FERTILITY AND STERILITY Copyright 1991 The American Fertility Society Printed on acid-free paper in U.S.A. The predictive value of idiopathic failure to fertilize on the first in vitro fertilization
More informationNeil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
More informationInfertility. Review and Update Clifford C. Hayslip MD Intrauterine Inseminations
Infertility Review and Update Clifford C. Hayslip MD Intrauterine Inseminations Beneficial effects of IUI not consistently documented in studies No deleterious effects on fertility 3-4 cycles of IUI should
More informationRelation between the Number and Size of Follicles in Ovulation Induction and the Rate of Pregnancy
Relation between the Number and Size of Follicles in Ovulation Induction and the Rate of Pregnancy Aseel Mosa Jabber M.SC.G.O. The department of Obstetrics and Gynecology, Faculty of Medicine Thi-qar university
More informationFemale Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Infertility Injectables Table of Contents Coverage Policy... 1 General Background...16 Coding/Billing Information...20 References...20 Effective Date...
More informationLiyan Duan 1, Shihua Bao 1, Kunming Li 1, Xiaoming Teng 1, Ling Hong 1 and Xiaoyu Zhao 2. Abstract. Introduction
doi:10.1111/jog.13305 J. Obstet. Gynaecol. Res. Vol. 43, No. 6: 1037 1042, June 2017 Comparing the long-acting and short-acting forms of gonadotropin-releasing hormone agonists in the long protocol of
More informationProspective randomized study on the cryopreservation of human embryos with dimethylsulfoxide or 1,2-propanediol protocols*t
FERTILITY AND STERILITY Vol. 63, No. I, January 1995 Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Prospective randomized study on the cryopreservation
More informationI.E.Messinis 1,4, S.Milingos 1, K.Zikopoulos 2, G.Hasiotis 3, K.Seferiadis 3 and D.Lolis 2
Human Reproduction vol.13 no.9 pp.2415 2420, 1998 Luteinizing hormone response to gonadotrophinreleasing hormone in normal women undergoing ovulation induction with urinary or recombinant follicle stimulating
More informationInfertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary
Subfertility Infertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary Infertility affects about 15 % of couples. age of the female. Other factors that
More informationRisk factors for spontaneous abortion in menotropintreated
FERTILITY AND STERILITY Copyright ~ 1987 The American Fertility Society Vol. 48, No. 4, October 1987 Printed in U.S.A. Risk factors for spontaneous abortion in menotropintreated women Michael Bohrer, M.D.*
More informationFollicular diameters in conception cycles with and without multiple pregnancy after stimulated ovulation induction
Human Reproduction Page 1 of 5 Hum. Reprod. Advance Access published December 17, 2004 doi:10.1093/humrep/deh677 Follicular diameters in conception cycles with and without multiple pregnancy after stimulated
More informationIVF Protocols: Hyper & Hypo-Responders, Implantation
IVF Protocols: Hyper & Hypo-Responders, Implantation Midwest Reproductive Symposium June 4-5, 4 2010 Subset : Hyper-Responders Mark R. Bush, MD, FACOG, FACS OBJECTIVE: Important goals for the PCOS patient
More informationOvarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy
Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy M.E. Coccia, F. Cammilli, L. Ginocchini, F. Borruto* and F. Rizzello Dept Gynaecology Perinatology and Human
More informationLeptin concentrations in the follicular phase of spontaneous cycles and cycles superovulated with follicle stimulating hormone
Human Reproduction vol.13 no.5 pp.1152 1156, 1998 Leptin concentrations in the follicular phase of spontaneous cycles and cycles superovulated with follicle stimulating hormone I.E.Messinis 1,4, S.Milingos
More informationEgg donation in an in vitro fertilization program: an alternative approach to cycle synchronization and timing of embryo transfer
FERTILITY AND STERILITY Copyright tl 1989 The American Fertility Society Printed on acid-free paper in U. S.A. Egg donation in an in vitro fertilization program: an alternative approach to cycle synchronization
More informationNew York Science Journal 2014;7(4)
The Minimal Stimulation Protocol for ICSI: An Alternative Protocol for Ovarian Stimulation Adel Elsayed Ibrahim, MD Assisted Reproductive Unit Azhar University Adel.sayed29@gmail.com Abstract: Background:
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Lyophilised powder for injection / 75 IU. Date of FAR:
Core Safety Profile Active substance: Urofollitropin Pharmaceutical form(s)/strength: Lyophilised powder for injection / 75 IU P - RMS: UK/H/PSUR/0059/001 Date of FAR: 04.12.2009 4.2 Posology and method
More informationlbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour
lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate
More informationLars G.Westergaard 1, Karin Erb, Steen Laursen, Per E.Rasmussen and Sven Rex
Human Reproduction vol.11 no.6 pp. 1209-1213, 19% The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertuization in
More informationEffects of functional ovarian cysts detected on the 7th day of gonadotropin-releasing hormone analog administration on the outcome of IVF treatment
FERTILITY AND STERILITY VOL. 74, NO. 5, NOVEMBER 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effects of functional
More informationSuperovulation with human menopausal gonadotropins is associated with endometrial gland-stroma dyssynchrony*
aes FERTILITY AND STERILITY Vol. 61, No.4, April 1994 Copyright ee) 1994 The American Fertility Society Printed on acid-free paper in U. S. A. r I Superovulation with human menopausal gonadotropins is
More informationOvulation induction in women age 40 and older: the importance of basal follicle-stimulating hormone level and chronological age*
FERTILITY AND STERILITY Vol. 58, No.4, October 1992 Copyright It! 1992 The American Fertility Society Printed on acid-free paper in U. S.A. Ovulation induction in women age 40 and older: the importance
More information